![]() |
Boehringer Ingelheim Initiates Phase III Clinical Trial With Novel Oral Agent In Adva
Boehringer Ingelheim announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer...
More... |
Re: Boehringer Ingelheim Initiates Phase III Clinical Trial With Novel Oral Agent In
I figured this was a weight loss med. Sounds encouraging..another oral HER tool.
|
| All times are GMT -7. The time now is 05:48 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021